Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 9/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 6/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.46 |
| ▸ | CLK3 | P49761 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22453170 | 0.90 | LRRK2 (0.56) | AXLLRRK2NTRK1NTRK2GSK3B | |
| SCHEMBL22445909 | 0.89 | LRRK2 (0.51) | AXLLRRK2 | |
| SCHEMBL22445823 | 0.89 | LRRK2 (0.51) | LRRK2 | |
| SCHEMBL22453166 | 0.88 | LRRK2 (0.51) | LRRK2 | |
| SCHEMBL22445852 | 0.87 | LRRK2 (0.51) | LRRK2NTRK1DYRK1ACLK2CLK3 | |
| SCHEMBL22453184 | 0.87 | LRRK2 (0.49) | LRRK2 | |
| SCHEMBL22453917 | 0.86 | LRRK2 (0.45) | LRRK2GSK3BDYRK1A | |
| SCHEMBL22453129 | 0.86 | LRRK2 (0.51) | LRRK2 | |
| SCHEMBL22445849 | 0.86 | LRRK2 (0.56) | LRRK2NTRK1 | |
| SCHEMBL22445874 | 0.86 | LRRK2 (0.49) | LRRK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | AXL 3001/4885LRRK2 1/4885NTRK1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.